Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “S-337395 will be administered per schedule specified in the arm description.”In the company’s words, NCT07214571 on ClinicalTrials.gov
- Tested for
- Respiratory Syncytial Virus Infections
- Main trialPhase 2
- “The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.”In the company’s words, NCT07214571 on ClinicalTrials.gov
Other drugs for Respiratory Syncytial Virus Infections
- RSVPreF3 OA vaccineGSK · Phase 3
- Human interferon α1b InhalationKexing Biopharm Co., Ltd. · Phase 3
- ABRYSVOPfizer · Phase 3
- ZiresovirShanghai Ark Biopharmaceutical Co., Ltd. · Phase 2/3
- ZelicapavirEnanta Pharmaceuticals, Inc · Phase 2
- Investigational hMPV vaccineSanofi · Phase 1/2
Coming up1
- 30 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Dec 2026 | A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease | |
| Phase 1Completed | 30 May 2024 | A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026